108 results about "Viral immunization" patented technology

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.

The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.

The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.

The invention discloses a method for preparing an African swine fever virus P30 and P54 yeast vaccine. The vaccine contains African swine fever virus strong immunogen protein P30, membrane structure protein P54, Fc fragments of swine IgG1 and IgA1 (namely Fc gamma, Fc alpha), and His purification tags. The method comprises the following steps: S1, connecting ASFV immunogen protein genes p30 and p54 with Fc gamma and Fc alpha in series; S2, respectively constructing transcription units of p30-Fc gamma and p54-Fc alpha in fusion expression in the yeast; S3, realizing series connection of the twotranscription units through in-vitro enzyme linking, yeast in-vivo conversion and homologous recombination technologies, and stably integrating the two transcription units into surface display type saccharomyces cerevisiae; and S4, carrying out genome level and protein level verification, and confirming to obtain two recombinant yeast strains of which the independent surfaces show and express theP30-Fc gamma and P54-Fc alpha fusion proteins, and a tandem composite expression type recombinant yeast strain of which the surface shows and expresses the two fusion proteins at the same time in S1.The strain is mature in production technology, suitable for large-scale production, safe to use and capable of inducing remarkable mucous membrane and humoral immune response of target animals.

This invention discloses monoclonal antibody against anti-LCDV immunoglobulin of Paralichthys olivaceus, which is excreted by hybridoma JF-lgM-H (CCTCC-C200631). The method comprises: immunizing Paralichthys olivaceus with LCDV inactivated by formalin to prepare antiserum, purifying Paralichthys olivaceus immunoglobulin, immunizing Balb / c mice as antigen, preparing hybridoma cells by cell engineering method, and screening the monoclonal antibody by immunoassay. Indirect ELISA and indirect immunofluorescent antibody assay show that this monoclonal antibody is located on the heavy chain (7-80 kDa) of the anti-LCDV immunoglobulin. The monoclonal antibody can be used for preparing reagents for detecting LCDV infection in early stage, and evaluating the immune effects of LCDV vaccine inactivated by formalin.

The invention discloses a gambogic acid cyclized analog, a preparation method and application thereof. The semi-synthesized gambogic acid cyclized analog is obtained by the extracted and purified gambogic acid through chemical synthesis and has a structural general formula I-III as the right formula, wherein substituent groups of A ring, B ring, C ring, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, R10, R11 or / and R12 contain glycosyl group, polyhydroxy, amino acid group, acyloxy group, phosphoric acid oxygen group, sulphonic acid oxygen group, alkoxyl group, aromatic oxygen group, heterocyclic oxygen group, mercapto group, substituted mercapto group, primary amine and secondary amines groups or / and substituted primary amine and secondary amines groups, and chain hydrocarbon or and cyclic group containing oxygen, sulphur, nitrogen, carbon or / and phosphor atoms, and one or combination of the substitution groups. The gambogic acid cyclized analog has anti-tumor, antivirus, antibacterial and antifungal pharmacology activities, can be used as anti-tumor, antivirus, immune, antibacterial and antifungal medicaments, and can be applied together with the known anti-tumor, antivirus, immune, antibacterial and antifungal medicaments.

The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity.

The invention discloses an immunity enhancing reagent comprising AAVs carrying molecule encoding genes of antibodies at immunodetection points, wherein the immunodetection points are one or several from PD-1, PD-L1 and CTLA-4. The AAVs carrying the molecule encoding genes of the antibodies at different immunodetection points are combined with each other, T cells, natural killer cells, cytotoxic T lymphocytes or cell factor induced killer cells and other immune cells are infected in vitro, and the antibodies at the immunodetection points are expressed and secreted after the infected immune cells are fed back to bodies of patients suffering from tumors, so that the combination of receptors at the immunodetection points and ligands of the receptors is blocked, the transfer of an immunosuppression signal is effectively blocked, the immune tumor suppression microenviroment is destroyed, the immune cell killing capacity is improved, and furthermore the curative effect of adoptive immune therapy is improved.

A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.

The invention relates to expression and application of bovine viral diarrhea virus (BVDV) type I E2 protein. The expression and the application have the advantages that (1) an expression and purification method for efficiently obtaining BVDV E2 protein is established and can be used for preparing the pure BVDV E2 protein; (2) a rabbit is immunized by the BVDV E2 protein to prepare an antibody; compared with an antibody prepared by whole-virus immune cattle, the antibody has good specificity and shallow background and is easy to determine; a secondary antibody is marked by FITC (Fluorescein Isothiocyanate) and an indirect fluorescence method is established, so that the sensitivity is better; the operation is simple: a pre-mixed solution is adopted so that operation time is shortened; (3) the pure BVDV E2 protein is used for covering, sealing conditions, blood serum and antibody preserving fluid are optimized, and a BVDV antibody indirect ELISA (Enzyme-Linked Immuno Sorbent Assay) method is established; a BVDV antibody indirect ELISA kit, which is sensitive and low in price, is assembled and a situation of dependence on imported BVDV antibody ELISA kits for a long period can be changed.

The invention discloses an immunity detection chip of prawn white spot syndrome virus (WSSV), comprising a chip carrier and an agarose gel layer which is paved on the chip carrier, wherein, the agarose gel layer is fixed with a plurality of antibody microarrays of 4*4, and chip-dedicated fences or Super PAP Pen scribings are used for separating the microarrays from each other. The invention comprises the following steps: adopting the sandwich method to detect the antigen; fixing the pathogenic polyclonal antibody (PcAb) on the chip slice base; taking the target organ tissue of the individual to be detected to prepare to-be-detected sample liquid; incubating directly the to-be-detected sample liquid with the chip which is fixed with PcAb to capture the antigen and lead the antigen to combine on the chip; adding a specific monoclonal antibody probe marked by fluorescence; and reading results through a CCD chip scanner. The invention has the advantage of detecting white spot syndrome virus (WSSV) in multiple samples simultaneously, and is applicable to the rapid and accurate detection of white spot syndrome virus (WSSV) of prawns / crabs in breeding production and the quarantine inspection of WSSV in import and export prawns / crabs.

The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The rabies virus immunogen can also be adsorbed to the metal salt.

The invention provides a Sabin strain poliovirus type III monoclonal antibody and an application thereof, and belongs to the field of immunology. After a mouse is immunized and inoculated with Sabin strain poliovirus type III, mouse spleen cells are fused with mouse myeloma cells, a hybridoma cell strain producing the anti-Sabin strain poliovirus type III specific monoclonal antibody is screened and has the preservation number of CGMCC No.9233, and the secreted monoclonal antibody has high titer, has strong neutralizing activity, and can effectively block infection of the poliovirus type III; at the same time, the antibody can specifically distinguish the poliovirus type III from poliovirus type I, poliovirus type II and other various enteroviruses, has good specificity, and can be used for preparing poliovirus type III antigen content detection kits and antibody detection kits, also can be used for identification detection of the poliovirus type III, and has the broad application prospect.

The invention provides a preparation method for a goose-origin reovirus inactivated vaccine. The preparation method comprises the following steps that a goose embryo is inoculated against reoviruses through an allantoic cavity, dead embryo allantoic fluids or live embryo allantoic fluids are collected within 24-144 h after incubation, and reovirus fluids are obtained; the reovirus fluids are inactivated through formaldehyde, Tween-80 is added to be mixed to serve as a water phase, and white oil, Span-80 and aluminium stearate are mixed to serve as an oil phase; and the water phase is added into the oil phase to be mixed uniformly, and the inactivated vaccine is obtained. According to the preparation method, the prepared goose-origin reovirus inactivated vaccine has high protective effects on a gosling, and is suitable for virus immunity of the gosling.

The invention discloses a multi-virus immunodetection device and method based on a smart phone and a micro-fluidic chip. The device is used for carrying out multi-virus immunodetection on a blood sample infected with viruses of a human body, a horizontally arranged mobile phone slot is formed in the middle of the upper surface of the shell, a horizontally arranged detection device, a reaction chipand a reagent chip are sequentially arranged above the mobile phone slot, and the reagent chip is driven by a lifting device to vertically move up and down. Reagent bottles with different depths andpenetrable adhesive films at the bottoms are designed, and separation and coupling of the reagent bottles and a sharp tube on the reaction chip is realized, and sample purification, incubation, colordevelopment and the like are integrated on one chip. The square air cavity is controlled to contract and expand by the electromagnetic clamp, so that the requirement of driving liquid to flow in different reaction steps is met, and the existing microplate reader can be replaced by only one smart phone for absorbance detection. The reaction chip is independent of other structures, different antibodies or antigens can be coated in reaction tubes in different reaction chips, and multi-virus detection is realized.

The invention discloses a recombinant porcine pseudorabies virus (Herpesviridae) strain used for expression of porcine circovirus type II ORF2 gene. Preservation number of the recombinant porcine pseudorabies virus strain is CCTCC No.V201315. According to the preparation method, PCV2ORF2 gene is inserted into common carrier PG so as to construct transferring plasmid PGO; monolayer ST cells are inoculated with PRVTK<-> / gG<-> / gE<-> virus by 2h of adsorption; ST cells are transfected with plasmid PGO, wherein fusion degree of the monolayer ST cells is 80 to 90%; the recombinant porcine pseudorabies virus PGO strain is obtained by plaque purification, and is used for immunization of mouse. It is shown by results that commercial PCV2 inactivated vaccine and a group immunized by the recombinant porcine pseudorabies virus PGO strain are both capable of inducing specific humoral immune response of mouse, antibody titers of both the commercial PCV2 inactivated vaccine and the group are obviously higher than that of a group immunized by DMEM medium, and difference is significant (p<0.05). It is shown by the results of mouse lymphocyte proliferation test that specific ceullar immune response caused by the group immunized by the recombinant porcine pseudorabies virus PGO strain is more obvious than that caused by the commercial PCV2 inactivated vaccine and the group immunized by DMEM medium, and difference is obvious (p<0.05). In addition, the group immunized by the recombinant porcine pseudorabies virus PGO strain is capable of resisting severe attack by PCV2. Therefore application of the recombinant porcine pseudorabies virus strain in development of a novel PCV2 vaccine is possible.

The present invention involves a new viral immunotherapy drug complex, and in particular, a viral immunotherapy drug complex for persistent hepatitis B infection. The present drug consists of antiviral drugs, immunoregulating drugs and a recombinant hepatitis B vaccine, for use in treating hepatitis B and in particular chronic hepatitis B infections. Antiviral drugs of the described drug complex are selected among α-IFN and nucleosides; the immunoregulating drugs are selected from among GM-CSF and similar.

The invention provides a new coronavirus SARS-CoV-2 broad-spectrum polypeptide antigen, a specific neutralizing antibody thereof and application, and belongs to the technical field of virus immunodetection. The new coronavirus SARS-CoV-2 broad-spectrum polypeptide antigen has an amino acid sequence shown as SEQ ID NO: 1, and can be specifically combined with a new coronavirus antibody through reaction with SARS-CoV-2 human positive serum. Based on the polypeptide sequence, triple SARS-CoV-2 broad-spectrum polypeptide tandem fusion protein is prepared by utilizing PCR, prokaryotic expression and protein purification technologies, a trimer mode of SARS-CoV-2S protein in a natural state is simulated, the fusion protein is used as an antigen to immunize mice, the SARS-CoV-2 specific neutralizing antibody can be generated, and the neutralizing antibody has good application prospects in SARS-CoV-2 anti-infection treatment, vaccine research and development and detection kit development.

The present invention provides a method of enhancing resistance of plants to one or multiple viruses, comprising introducing to a plant cell, and preferably expressing therein, a nucleotide sequence encoding a virus-encoded polypeptide. The present invention provides a method of enhancing the proportion of virus-resistant or virus-immune lines obtained from a single transformation experiment comprising introducing to a plant cell, a nucleotide sequence encoding a virus-encoded polypeptide operably in connection with a strong promoter sequence. The present invention provides novel gene sequences encoding the coat proteins of a virus and novel dysfunctional replicase sequences as well as gene constructs comprising same, in particular binary vector constructs suitable for introducing into plants and expressing the genes therein. The present invention provides and methods using same to enhance viral resistance in plants. The present invention provides novel methods of testing transgenic plants for the presence of a transgene.

A method and apparatus prevents hacker code from infecting an application program by requiring decryption of the application program prior to running the application program on a computer. The method includes steps of: providing a security device that is a separate unit from components necessary to operate the computer; storing a symmetric private key on the security device; using the device symmetric private key to produce an encrypted application program upon first installation; thereafter decrypting that part of the encrypted application program needed implement a command to run the application program; and, decrypting, on the fly, only those follow-on parts of the encrypted application program needed to perform functions called for during operation of the application program.

The invention discloses a method for preparing an avian influenza virus and an inactivated vaccine thereof with Vero passage cells. According to the method disclosed by the invention, the Vero passage cells are adopted to replace chicken embryo to culture influenza virus, so that the problems of chicken embryo remnant and exogenous virus inflection are solved and the immunogenicity of the cultured virus is more stable. On the other hand, for avoiding the phenomenon that the cracking of HA is influenced because protease is acted by an inhibitor in a maintaining liquid to inactivate, pancreatinis coated with chitosan and then is added in a cell maintaining liquid, so that the pancreatin is slowly released in the maintaining liquid and the defect that the cracking of hemagglutinin is influenced because the pancreatin is inactivated in the reproduction process of viruses is overcome. In addition, the probability that the cells are polluted since the pancreatin is added for multiple timesis avoided. The virus cultured by the method disclosed by the invention is high in titer and favorable in stability and is suitable for large-scale vaccine production.

The invention provides a monoclonal antibody for a duck tembusu virus and application. A hybridoma cell strain 1-E11 with the collection number CCTCCNO being C2014219 and a hybridoma cell strain 4-C3 with the collection number CCTCCNO being C2014220 of the monoclonal antibody resisting the duck tembusu virus are obtained by using a purified duck-tembusu-virus immunized Balb / c mouse; a colloidal-gold test strip is prepared by utilizing the monoclonal antibody secreted by the cell strains, the 1-E11 is adopted as a labeled monoclonal antibody, 4-C3 is used as a coated monoclonal antibody, and the obtained test strip has the characteristics of fast and sensitive detection and good specificity. A result is clear and the judgment is easy; the carry and the use are convenient, and the detection cost for disease is saved.

The invention provides a Sabin strain poliovirus type II monoclonal antibody and an application thereof, and belongs to the immunology field. After a mouse is immunized and inoculated with Sabin strain poliovirus type II, mouse spleen cells are fused with mouse myeloma cells, a hybridoma cell strain producing the anti-Sabin strain poliovirus type II specific monoclonal antibody is screened and has the preservation number of CGMCC No.9232, and the secreted monoclonal antibody has high titer, has strong neutralizing activity, and can effectively block infection of the poliovirus type II; at the same time, the antibody can specifically distinguish the poliovirus type II from poliovirus type I, poliovirus type III and other various enteroviruses, and can be used for preparing type II antigen content detection kits and antibody detection kits of the poliovirus type II and a poliomyelitis inactivated vaccine, also can be used for identification detection of the poliovirus type II, and has the broad application prospect.

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

The invention provides a novel coronapneumonia virus receptor ACE2 affinity adsorbent as well as a preparation method and application thereof. The novel coronapneumonia virus receptor ACE2 affinity adsorbent comprises a carrier microsphere and a novel coronapneumonia virus receptor ACE2 aptamer combined on the surface of the carrier microsphere. The surface of the carrier microsphere is modified by amino, the surface of the novel coronapneumonia virus receptor ACE2 aptamer is modified by carboxyl, and the amino on the surface of the carrier microsphere and the carboxyl on the surface of the novel coronapneumonia virus receptor ACE2 aptamer form a stable amido bond. The virus adsorbent has the advantages of simple structure, easily available raw materials, high coupling efficiency and stability, simple and controllable preparation method, one-step synthesis, high yield and good development prospect. The aptamer can be recycled after being recovered and enriched, so that the cost is greatly reduced. The novel coronavirus receptor ACE2 virus adsorbent has a huge application prospect in the field of novel coronavirus immune adsorption.